ArticleNeurology and therapy2026
Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCerebrospinal fluid (CSF) biomarker ratios (amyloid-β [Aβ]42/Aβ40, phosphorylated-tau [pTau]/Aβ42, and total tau [tTau]/Aβ42) are lower-cost alternatives to amyloid positron-emission tomography (PET) for Alzheimer's disease diagnosis. Among these CSF biomarker ratios, it is not clear whether concordance with amyloid PET is highest with Aβ42/Aβ40, pTau/Aβ42, or tTau/Aβ42. To evaluate this, we conducted a diagnostic test accuracy meta-analysis.
methodsMedline and Embase were searched for articles published between January 2008 and February 2026 reporting concordance of ≥ 1 CSF biomarker ratio with amyloid PET. Statistical analyses were performed using the bivariate model of Reitsma with the R package mada v0.5.11.
resultsThis quantitative meta-analysis comprised 38 studies, including a total of 7504 participants, with 35 studies available for statistical analysis. All three CSF biomarker ratios (Aβ42/Aβ40, pTau/Aβ42, and tTau/Aβ42) were highly concordant with amyloid PET. However, the pTau/Aβ42 ratio showed numerically higher overall percent agreement with amyloid PET positivity (90.4%) versus Aβ42/Aβ40 (89.5%) or tTau/Aβ42 (89.2%), a significantly higher area under the curve (0.955) versus Aβ42/Aβ40 (0.921, p value for difference 0.018), and a significantly lower false positive rate (0.116) versus Aβ42/Aβ40 (0.153, p value for difference 0.015).
conclusionpTau/Aβ42 showed the highest overall concordance with amyloid PET positivity and the lowest false positive rate versus Aβ42/Aβ40 or tTau/Aβ42.
Indexed as
Identifiers
42911504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.